Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.59 |
| ▸ | F10 | P00742 | 5/20 | 0.58 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.56 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.54 |
| ▸ | CDC25B | P30305 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SELP | P16109 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | RPA1 | P27694 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2021012 | 1.00 | PTPN1 (0.59) | PTPN1F10HSD11B1PTPN2CDC25B | |
| SCHEMBL29626875 | 1.00 | PTPN1 (0.59) | PTPN1F10HSD11B1PTPN2CDC25B | |
| SCHEMBL30997030 | 0.87 | PTPN1 (0.59) | PTPN1F10HSD11B1PTPN2CDC25B | |
| SCHEMBL17027695 | 0.81 | HSD11B1 (0.57) | PTPN1F10HSD11B1PTPN2CDC25B | |
| SCHEMBL3513520 | 0.81 | HSD11B1 (0.57) | PTPN1F10HSD11B1PTPN2CDC25B | |
| SCHEMBL29552568 | 0.80 | PTPN1 (0.41) | PTPN1F10HSD11B1PTPN2CDC25B | |
| SCHEMBL29404708 | 0.80 | PTPN1 (0.41) | PTPN1F10HSD11B1PTPN2CDC25B | |
| SCHEMBL29366469 | 0.80 | PTPN1 (0.41) | PTPN1F10HSD11B1PTPN2CDC25B | |
| SCHEMBL29421727 | 0.80 | PTPN1 (0.41) | PTPN1F10HSD11B1PTPN2CDC25B | |
| SCHEMBL3490260 | 0.80 | F10 (0.66) | PTPN1F10HSD11B1PTPN2CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155769-B1 | TISSUE DEGENERATION PROTECTION | UNIV LEUVEN KATH (BE) | 2012-06-27 | — | — | EP | claimed |
| US-20100099640-A1 | TISSUE DEGENERATION PROTECTION | GEUNS JOANNES | 2010-04-22 | — | — | US | claimed |
| EP-2155769-A2 | TISSUE DEGENERATION PROTECTION | Katholieke Universiteit Leuven (BE) | 2010-02-24 | — | — | EP | claimed |
| WO-2008134828-A2 | TISSUE DEGENERATION PROTECTION | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2008-11-13 | — | — | WO | claimed |
| US-9491963-B2 | Sweetness enhancers, compositions thereof, and methods for use | THE COCA-COLA COMPANY (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150216219-A1 | Sweetness Enhancers, Compositions Thereof, and Methods for Use | THE COCA-COLA COMPANY | 2015-08-06 | — | — | US | disclosed |
| US-9012520-B2 | Sweetness enhancers, compositions thereof, and methods for use | THE COCA-COLA COMPANY (US) | 2015-04-21 | — | — | US | disclosed |
| EP-2155769-B1 | TISSUE DEGENERATION PROTECTION | UNIV LEUVEN KATH (BE) | 2012-06-27 | — | — | EP | disclosed |
| US-20110160311-A1 | Sweetness Enhancers, Compositions Thereof, and Methods for Use | THE COCA-COLA COMPANY | 2011-06-30 | — | — | US | disclosed |
| US-20100099640-A1 | TISSUE DEGENERATION PROTECTION | GEUNS JOANNES | 2010-04-22 | — | — | US | disclosed |
| EP-2155769-A2 | TISSUE DEGENERATION PROTECTION | Katholieke Universiteit Leuven (BE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008134828-A2 | TISSUE DEGENERATION PROTECTION | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099640-A1 | TISSUE DEGENERATION PROTECTION | SORD, CASP3, TXNRD2 | PTPN1 3492/4885F10 551/4885HSD11B1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.